Sanofi: FDA lifts clinical hold on fitusiran
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
BofA/Merrill Lynch Remains Sidelined on Sanofi (SNY) Following R&D Meeting
December 18, 2017 9:20 AM ESTBofA/Merrill Lynch reiterates a Neutral rating and $49.00 price target on Sanofi (NYSE: SNY) following the company's R&D Q&A session.
Although Sanofi suggested its PIII lung program for cemiplimab has PFS as a primary endpoint, it clarified today that the... More
